Abstract: Methods of making blended, isoporous, asymmetric (graded) films (e.g. ultrafiltration membranes) comprising two or more chemically distinct block copolymers and blended, isoporous, asymmetric (graded) films (e.g. ultrafiltration membranes) comprising two or more chemically distinct block copolymers. The generation of blended membranes by mixing two chemically distinct block copolymers in the casting solution demonstrates a pathway to advanced asymmetric block copolymer derived films, which can be used as ultrafiltration membranes, in which different pore surface chemistries and associated functionalities can be integrated into a single membrane via standard membrane fabrication, i.e. without requiring laborious post-fabrication modification steps. The block copolymers may be diblock, triblock and/or multiblock mixes and some block copolymers in the mix may be functionally modified. Triblock copolymers comprising a reactive group (e.g.

Abstract: The present invention relates to methods and a kit for enhancing the translation ability of an RNA molecule. The methods involve the use of an RNA molecule comprising a methylated adenosine residue in a 5? untranslated region (UTR). Also disclosed are methods for eIF4E-independent translation of an RNA molecule and treatment methods.

Abstract: A high-power transmitter with a fully-integrated phase Iocking capability is disclosed and characterized. Also provided herein is a THz radiator structure based on a return-path gap coupler, which enables the high-power generation of the disclosed transmitter, and a self-feeding oscillator suitable for use with the transmitter.

Abstract: The present invention is directed to transduced T cells expressing at least 100,000 molecules of human somatostatin receptor 2 (SSTR2), which improves PET/CT imaging sensitivity. The present invention is also directed to transduced T cells expressing SSTR2 and chimeric antigen receptor (CAR). In one embodiment, the CAR is specific to human ICAM-1 and the CAR comprises a binding domain that is scFv of anti-human ICAM-1, or an I domain of the ?L subunit of human lymphocyte function-associated antigen-1. In another embodiment, the CAR is specific to human CD19, and the CAR comprises a binding domain that is scFv of anti-human CD19. The present invention is further directed to using the above transduced T cells for monitoring T cell distribution in a patient by PET/CT imaging and/or treating cancer.

Abstract: There is set forth herein an optomechanical device which can comprise a first mirror and a second mirror forming with the first mirror a cavity. In one aspect the first mirror can be a movable mirror. The optomechanical device can be adapted so that the first mirror is moveable responsively to radiation force.

Abstract: Provided herein are methods of isolation and identification of post-natal hemogenic endothelial cells. Further provided are substantially purified populations of post-natal hemogenic endothelial cells, compositions of post-natal hemogenic endothelial cells, and methods to utilize hemogenic endothelial cells to regenerate the hematopoietic system in a subject.

Abstract: The invention relates to a plant that includes a transgene encoding a heterologous polypeptide conferring on plant expressing said polypeptide resistance to a hemipteroid sap-sucking insect. The transgene is also expressed in a plant component (such as a leaf). Typically, expression of such polypeptides deters feeding by insects such as psyllids (such as an Asian citrus psyllid, the African citrus psyllid, or the American citrus psyllid). Exemplary plants useful in the invention are citrus or solanaceous plants.

Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.

Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.

Abstract: Disclosed herein are nanoparticle immunoconjugates useful for therapeutics and/or diagnostics. The immunoconjugates have diameter (e.g., average diameter) no greater than 20 nanometers (e.g., as measured by dynamic light scattering (DLS) in aqueous solution, e.g., saline solution). In certain embodiments, the conjugates are silica-based nanoparticles with single chain antibody fragments attached thereto.

Abstract: The invention provides a compound of formula (I): wherein R is as described herein. The invention also provides a process for the preparation of the compound.

Abstract: Aspects of the disclosure relate to a method for treating idiopathic pulmonary fibrosis (IPF) in a patient with N-acetylcysteine (NAC) comprising administering NAC to a patient after a sample from the patient has been genotyped and determined to be any one of: a) homozygous or heterozygous for a thymine at the single nucleotide polymorphism rs3750920; b) homozygous or heterozygous for guanine at the single nucleotide polymorphism rs5743894; or c) homozygous or heterozygous for thymine at the single nucleotide polymorphism rs35705950.

Abstract: Tools and techniques for providing joint position error test system are provided. A system includes a head sensing unit coupled to a joint position error processor. The head sensing unit may include a positional sensor and further be configured to be coupled to the head of a test subject. The joint position error processor may include a processor, and non-transitory computer readable media comprising instructions executable by the processor to record reference sensor data from the positional sensor when the test subject's head is in a reference position, record return sensor data when the test subject's head is in a return position. The instructions may further be executable to determine a position error based on the reference sensor data and the return sensor data, and to further determine the presence of a condition of the test subject based on the position error.

Abstract: The present invention relates to a probiotic cell transformed with a construct suitable to overexpress and display on the surface of the probiotic cell a fusion protein comprising at least a portion of a transport protein coupled to at least a portion of one or more antigenic proteins or peptides. Probiotic-derived vesicles displaying this fusion protein as well as methods of inducing an immune response using the probiotic cells or vesicles are also disclosed.

Abstract: Disclosed herein are methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with HIV or has been the recipient of a solid organ transplant.

Abstract: The present invention relates to a method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting glutaminase C activity in the cell or tissue under conditions effective to reduce production of glutamate from glutamine. Compounds for carrying out this method are also disclosed and include those of formula (III): wherein B, R1c, R2c, m, and n are defined herein.

Abstract: The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.

Abstract: An active electronic device that enables bidirectional communication over a single antenna or path is disclosed. The device may be characterized by a forward path (from an input to an antenna port) offering high gain, and a reverse path (to a receiver port) that can be configured as an finite impulse response (“FIR”) filter. An amplifier of the device is disclosed, the amplifier allowing for tuning of output resistance using passive mixers.

Abstract: Methods and systems to produce product compositions comprising caprylate products using chain-elongating bacteria. For example, the caprylate product in the product composition is n-caprylic acid (C8) and the n-caprylic (C8) to n-caproic (C6) acid ratio is higher than 1:1. These methods use chain elongation towards C8 rather than C6. High n-caprylate productivity and specificity was accomplished by: 1) feeding a substrate with, for example, ethanol as the carbon source or alternatively, a high ethanol-to-acetate ratio as the carbon source; 2) extracting caprylate product(s) (e.g., n-caprylate product) from the bioreactor broth; and 3) acclimating an efficient chain-elongating microbiome. The methods can produce caprylate products such as, for example, n-caprylic acid, which is a higher value chemical than C4 and C6.

Abstract: An encapsulation system and method including a solution having a first system with a first rate of removal, a second system with a second rate of removal, and a material soluble in the first system, but not soluble in the second system. The first rate of removal is quicker than the second rate of removal, and removal of the first system from the solution creates a concentration of the second system and the material migrates around the second system. Thus, the material creates a shell around the second system, generating a capsule with a shell of the material and a core of the second system. Such material may include a polymer, copolymer, or block copolymer, while the second system is poor solvent for the material, such as hexadecane or Oil Red O. The first system is a good solvent for the material and is readily removable from solution via evaporation during processes like electrospraying.